Major pharmaceutical companies, including Pfizer, Eli Lilly, and Amgen, are competing in the GLP-1 weight loss drug market.

The entities involved

• Pfizer →

  American multinational pharmaceutical and biotechnology corporation

  • Dave Long trained at Fort Knox after graduating from Boardman High School and later worked for Pfizer.Mon 05:00
  • MarketBeat's screener has identified a list of dividend stocks.Sun 22:22
• Amgen →

  American multinational biopharmaceutical company

  • Amgen, City of Hope, and the California Community Foundation are involved in a life sciences and bioscience economic summit held in Downtown Los Angeles.Mon 12:08
  • Geode Capital Management increased its stake in Amgen stock and filed the disclosure with the SEC.Mon 02:05
• Eli Lilly and Company →

  American pharmaceutical company

  • ExxonMobil, Berkshire Hathaway, and Eli Lilly are top holdings in the Avantis ETF.Mon 17:18
  • The FDA approved Olumiant for pediatric indications on September 1, 2026.Mon 05:59

Related events

• Eli Lilly and Novo Nordisk both launched oral GLP-1 medications this year, marking a major competitive development in the market.Aug 1
• GLP-1 drugs are identified as the primary cause of weight loss, accompanied by commentary on the industry's power over regulatory agencies.Sep 14
• Eli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.Sep 14
• Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.Jun 7
• Eli Lilly and Company received full FDA approval, expanded a safety study into India, and broke ground on a new facility in Houston while competing in the GLP-1 market.Wed 22:45